HCID 58097144, compound → HCID 178519566, compound

Participants

Reaction Conditions

Reaction Steps

71 mg of 5-(4-((6-((1-tert-butyl-1H-pyrazol-5-yl)amino)pyridin-2-yl)methyl)-1-(2-fluoro-3-(trifluoromethyl)benzoyl)piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-one was dissolved in 1.5 ml of formic acid at room temperature, followed by stirring the reaction mixture at 90° C. overnight. The reaction mixture was cooled to room temperature, and concentrated in vacuo. The resulting residue was basified with saturated aqueous sodium bicarbonate solution, and extracted with ethyl acetate. The ethyl acetate solution was dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated in vacuo. The resulting residue was purified by a preparative thin-layer chromatography (Kieselgel™ 60F254, Art5744 (Merck), chloroform/methanol=10/1) to give the title compound as a pale yellow solid.

Provenance & Evidence